When was Kiyatec founded?

Kiyatec was founded in 2005 and raised its 1st funding round 4 years after it was founded.

Where is Kiyatec located?

Kiyatec is headquartered in Pendleton, United States.

How many employees does Kiyatec have?

As of Jul 31, 2026, the latest employee count at Kiyatec is 14.

Is Kiyatec a funded company?

Kiyatec is a funded company, having raised a total of $29.5M across 13 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Feb 27, 2009.

When was the latest funding round of Kiyatec?

Kiyatec's latest funding was a $***** Series C round on Nov 13, 2025, with participation from 0 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $1.23B in funding in 2026 to date.

Where does Kiyatec rank among its competitors?

Kiyatec ranks 37th amongst 706 active competitors, of which 199 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was GRAIL, which secured $110M in Jun, 2026.

Who are the top competitors of Kiyatec?

Kiyatec's top competitors include Natera, Guardant Health and LifeCell. Among them, GRAIL secured the most recent funding round in June, 2026.

Kiyatec - 2026 Company Profile, Team, Funding & Competitors

Kiyatec is a series C company based in Pendleton (United States), founded in 2005. It operates as a Develops 3D phenotypic cell-based assays and diagnostic solutions for prediction of patients’ response to cancer drug treatment. Kiyatec has raised $29.5M in funding from investors like VentureSouth, Bruker and SCRA. The company has 706 active competitors, including 199 funded and 138 that have exited. Its top competitors include companies like Natera, Guardant Health and LifeCell.

Company Details

Kiyatec specializes in developing solutions for the prediction of patient's response to cancer drug treatment, with a focus on data correlation to human clinical outcomes. It develops live phenotypic 3D cell-based models for drug response profiling and applies them to generate information relevant to preclinical testing, clinical trials, and clinical diagnostics applications. This information helps in drug selection, minimizing clinical trials failures, and maximizing patient outcomes in the clinic.

Website: kiyatec.com
Social

Key Metrics

Founded Year

2005

Location

Pendleton, United States

Stage

Series C

Total Funding

$29.5M in 13 rounds

Latest Funding Round

Series C, Nov 13, 2025, $*****

Investors

VentureSouth & 14 more

Ranked

37^th among 706 active competitors

Employee Count

14 as on Jul 31, 2026

Similar Companies

Natera & 901 more

View Kiyatec's full profile

Kiyatec is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Kiyatec Inc. CIN: 1547577 , United States, Active		$1M - $5M (As on Nov 27, 2017)	-	-

Kiyatec has raised a total funding of $29.5M over 13 rounds. Its first funding round was on Feb 27, 2009. Kiyatec has 15 institutional investors.

Here is the list of recent funding rounds of Kiyatec:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 13, 2025	6238103	Series C	2287408	9732096	7270458	2871800
Oct 22, 2024	4059884	Series C	9739532	3937696	2987227	8409137
May 18, 2023	7831352	Series C	8668426	1332966	9740586	Brain Tumor Investment Fund & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Kiyatec's funding rounds and investors

Kiyatec's Board of Directors

Kiyatec's board has 18 active members. Jason Robart, Bruce Nash, Bob Silverman, Eric Perreault, David E. Orr, Christopher Brotherton, Christine Dixon Thiesing, Gregory Zaic, David E Orr, Robert J. Silverman, Martin Ettlemyer, Scott Isacksen, Melissa Rayner, Christine Dixon Thiesing, Robert Silverman, Matthew R. Gevaert, H. Lee Higdon III and Matthew Gevaert are independent board members.

Here is the list of Kiyatec's board of directors:

Name	Type	Representing	Status	Duration
Jason Robart	Independent board member	-	Current	3y 8m
mie{qer	Independent board member	-	Current	2y 5m
euwerde	Independent board member	-	Current	5y 9m
fppgmex	Independent board member	-	Current	9y 8m
zwehmae	Independent board member	-	Current	9y 3m
xhdacl{	Independent board member	-	Current	9y 1m
afsvctv	Independent board member	-	Current	8y 2m
ebrssuy	Independent board member	-	Current	4y 8m
edueovs	Independent board member	-	Current	9y 4m
ypxzfjc	Independent board member	-	Current	3y 8m
sxniupc	Independent board member	-	Current	4y 4m
qpjxnde	Independent board member	-	Current	7y 9m
mcehwij	Independent board member	-	Current	4y 3m
mpnqtzm	Independent board member	-	Current	4y 9m
xvelptn	Independent board member	-	Current	1y 3m
ptganc{	Independent board member	-	Current	5y 4m
nwuvxcm	Independent board member	-	Current	9y 6m
mjpmfqo	Independent board member	-	Current	8y 8m

Kiyatec's employee count trend

Kiyatec has 14 employees as of Jul 26. Here is Kiyatec's employee count trend over the years:

Uncover Kiyatec's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Kiyatec include Natera, Guardant Health and LifeCell. Here is the list of Top 10 competitors of Kiyatec, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Natera 2004, Redwood City (United States), Public	Developer of cell-free DNA testing for oncology, women’s health, and organ health	$152M	Harmony Partners, Bain Capital Life Sciences ... & 18 others	77/100
2nd	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	SoftBank Vision Fund, Lightspeed Venture Partners ... & 25 others	75/100
3rd	LifeCell 2004, Chennai (India), Series B	A stem cell banking company specializing in cord blood and tissue preservation	$61.2M	Orbimed, Helion Venture Partners & 74 others	74/100
4th	Foundation Medicine 2010, Cambridge (United States), Acquired	Provider of genomics-based diagnostics test for cancer	$96.5M	Redmile Group, Deerfield & 11 others	70/100
5th	Prenetics 2009, Hong Kong (China), Public	Online platform for genetic and diagnostic health testing that helps identify health risks	$67.6M	Apis Partners, Beyond Ventures & 22 others	69/100
6th	GRAIL 2016, Menlo Park (United States), Public	Developer of a screening platform for circulating tumor DNA to detect cancer	$2B	Arch Venture Partners, Hillhouse & 52 others	69/100
7th	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 31 others	69/100
8th	Myriad Genetics 1991, United States, Public	Developer of molecular diagnostics and personalized medicine for cancer	-	Grayhawk Capital, TriplePoint Capital & 6 others	68/100
9th	Bit.bio 2016, Cambridge (United Kingdom), Series C	Manufacturer of programmed human cells for research and drug discovery	$266M	M&G, Foresite Capital & 53 others	67/100
10th	Foresight Diagnostics 2020, Aurora (United States), Acquired	Developer of minimally-invasive liquid biopsy test for the detection of cancer	$104M	Foresite Capital, Bluebird Ventures & 6 others	66/100
37th	Kiyatec 2005, Pendleton (United States), Series C	Develops 3D phenotypic cell-based assays and diagnostic solutions for prediction of patients’ response to cancer drug treatment	$29.5M	NMT Capital, AIM Group & 13 others	55/100